Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Go back to Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)| Seattle Genetics Inc /wa (NASDAQ: SGEN) | Delayed: 228.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.74 | 52 Week High | $75.36 | |||
| Open | $22.94 | 52 Week Low | $26.02 | |||
| Day High | $228.74 | P/E | N/A | |||
| Day Low | $228.74 | EPS | $-0.51 | |||
| Volume | 759,302 | |||||
